Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting BioMarin significant royalty payments.
Two medicine companies stopped arguing about who owns what inventions, and now one will pay the other money regularly. When companies stop fighting and make deals, it usually means they can focus on making and selling their medicines instead of spending time in court.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.